Research
We engineer advanced LVs that co-deliver multiple payloads with controlled expression and improved immune targeting, enabling programmable therapeutic responses.
We are employing vectors to genetically engineer cancer and immune cells to explore new therapeutic interventions and unravel new biological insights.
Tumor vaccines can expand and activate endogenous cytotoxic T cells. We aim at identifying innovative platforms based on the use of viral vectors.